Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2017 16:10 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Announces $10 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Into 2019

NORCROSS, Ga., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it entered into a $10...
December 14, 2017 09:30 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Provides Corporate Update at Annual Meeting

Dr. Peter Traber, CEO and CMO, reviews results of NASH-CX trial that demonstrated statistically significant and clinically meaningful effects in patients who had NASH cirrhosis but did not have...
December 11, 2017 09:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Webcast Corporate Update at Annual Meeting of Shareholders

NORCROSS, Ga., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the Company will...
December 05, 2017 08:15 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Announces Results from Phase 2b NASH-CX Trial

Statistically significant and clinically meaningful effects observed in NASH cirrhosis patients without esophageal varices treated with GR-MD-02 Conference Call at 8:30 A.M. ET to Present Top Line...
December 04, 2017 16:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017

NORCROSS, Ga., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, will issue a press release announcing...
November 13, 2017 09:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017

NORCROSS, Ga., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that Peter G. Traber, M.D.,...
November 13, 2017 08:30 ET | Source: Galectin Therapeutics Inc.; Providence Cancer Institute

Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial

NORCROSS, Ga., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute today...
November 07, 2017 08:15 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business Update

All 52 weeks of infusions and 100% of the doses have been administered in the NASH Cirrhosis, NASH-CX Phase 2b Clinical Trial Top Line Results of NASH-CX Phase 2b Clinical Trial Expected to be...
October 20, 2017 08:30 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis

NORCROSS, Ga., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that Dr. Raj...
September 25, 2017 08:30 ET | Source: Galectin Therapeutics

Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017

NORCROSS, Ga., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced Peter G. Traber, M.D., the...